We conducted a detailed analysis by expression profiling of CEACAM6 in several PDA types, tumor-stromal cells, and PDA cell lines to elucidate expression across PDA tumor types, effect on survival, association with the stroma, immune environment, relevance to KRAS mutations, proteomics and tumor growth potential of CECACAM6 knockout in PDA cells. This evidence concerns the gene KRAS and Patent ductus arteriosus.